These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Protecting FDA's ability to protect public health. Taylor MR Food Drug Law J; 2006; 61(4):805-8. PubMed ID: 17180774 [No Abstract] [Full Text] [Related]
5. Advisory committees" critical to the FDA's product review process. Rados C FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199 [No Abstract] [Full Text] [Related]
6. The FDA's new drug rating system. Ohio Med; 1991 Mar; 87(3):133-4. PubMed ID: 2030884 [No Abstract] [Full Text] [Related]
7. FDA'S food ingredient approval process: Safety assurance based on scientific assessment. Rulis AM; Levitt JA Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884 [TBL] [Abstract][Full Text] [Related]
9. No dillydallying: Barton. Proposed legislation in response to GAO report on FDA's slow debarment. Rhea S Mod Healthc; 2009 Oct; 39(43):12-3. PubMed ID: 19972653 [No Abstract] [Full Text] [Related]
10. Women's health advocates dismayed at FDA's Plan B decision. Ready T Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017 [No Abstract] [Full Text] [Related]
11. FDA's decision on Plan B: a surrogate for lack of commitment to women's health. Merkatz RB J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214 [No Abstract] [Full Text] [Related]
12. DSHEA provisions confine FDA's authority to issue regulations that concern allegedly adulterated dietary supplements. McNamara SH; Siegner AW; Phelps EP Food Drug Law J; 1999; 54(4):595-8. PubMed ID: 11824456 [No Abstract] [Full Text] [Related]
13. FDA's emergency research rule: an inch given, a yard taken. Gillenwater GE Food Drug Law J; 2008; 63(1):217-56. PubMed ID: 18561460 [No Abstract] [Full Text] [Related]
14. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process. Aziz KJ; Sliva CA; Gutman SI Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487 [No Abstract] [Full Text] [Related]
15. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise. O'Reilly JT Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965 [No Abstract] [Full Text] [Related]
16. Food industry initiatives to improve the FDA's food ingredient review processes. Pape SM Food Drug Law J; 1996; 51(3):413-21. PubMed ID: 11797718 [No Abstract] [Full Text] [Related]
17. An overview of FDA medical device regulation as it relates to deep brain stimulation devices. Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274 [TBL] [Abstract][Full Text] [Related]
18. Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Interim final rule. Food and Drug Administration, HHS Fed Regist; 2007 Jun; 72(121):34959-69. PubMed ID: 17674485 [TBL] [Abstract][Full Text] [Related]
19. Remarks of the Commissioner of Food and Drugs. Henney JE Food Drug Law J; 1999; 54(1):1-3. PubMed ID: 11794304 [No Abstract] [Full Text] [Related]